Thursday, April 30, 2020

7:30-8:00 am  Breakfast

8:00-8:45 am  Welcome and Overview
  • Lisa Yue and Steven Lipshultz, MD

8:45-10:45 am  Dilated Cardiomyopathy
  Session Leaders: Steve Lipshultz, MD, Daphne Hsu, MD, Paul Kantor, MBBCh, MSc
  • How effectively do we currently risk stratify and tailor medical therapy for DCM?
    Daphne Hsu, MD
  • Which new drug therapies are under investigation for DCM?
    Robert Shaddy, MD
  • When and how does dilated cardiomyopathy recover?
    Melanie Everitt, MD
  • How do we improve quality and maximize value in the care of dilated cardiomyopathy?
    Kimberly Lin, MD
  • Point Counterpoint: How should we design research studies on dilated cardiomyopathy?
    o Observational studies are the most useful approach.
      Bill Mahle, MD
    o Clinical trials are the most useful approach.
      Christopher Almond, MD, MPH
  • FDA perspective on approval of clinical trials.
    Lynn Yao, MD
  • General discussion and summary

10:45-11:00 am  Coffee Break
11:00-12:15 pm  **Hypertrophic Cardiomyopathy**  
Session Leaders: Charlie Canter, MD, Steve Colan, MD, Robert Weintraub, MBBS

- What are the differences between non-sarcomeric versus sarcomeric HCM and should they have their own management scheme?  
  Anne Murphy, MD
- How should pediatric HCM be defined?  
  Steven Colan, MD
- Are P-G+ normal, diseased, or somewhere in between? / Role of genetic testing in clinical management?  
  Carolyn Ho, MD
- What is the optimal imaging strategy for pediatric HCM: echo, MRI, or a hybrid approach?  
  Elfriede Pahl, MD
- What is the optimal evaluative or surveillance protocol for pediatric HCM, and the minimum dataset for ongoing clinical care?  
  Elfriede Pahl, MD
- How should HCM diagnosed in infancy be evaluated and managed?  
  Charlie Canter, MD
- Indications for surgical relief of LV outflow obstruction.  
  Robert Weintraub, MBBS
- Guided Discussion

12:15-1:15 pm  **Lunch**

1:15-2:25 pm  **Hypertrophic Cardiomyopathy Continued**  
Session Leaders: Charlie Canter, MD, Steve Colan, MD, Robert Weintraub, MBBS

- What is the optimal management strategy to minimize sudden death in children with HCM?  
  Juan Kaski, MD
- Debate: the pros and cons of pediatric HCM±ICD participation in competitive athletics  
  George Van Hare, MD and Jeffrey Kim, MD
- The epidemiology and global burden of hypertrophic cardiomyopathy  
  Paul Barach, MD

2:25-2:40 pm  **Afternoon Break**

2:40-4:40 pm  **Genetics of Cardiomyopathy**  
Session Leaders: Wendy Chung, MD, PhD, Shelley Miyamoto, MD, Stephanie Ware, MD, PhD

- Breaking News: Genetics of the primary cardiomyopathies.  
  Stephanie Ware, MD, PhD
- The power of genes.  
  Wendy Chung, MD, PhD
• Update on gene-directed therapy for primary cardiomyopathies.  
  Anjali Owens, MD

• Which new gene therapies are under investigation?  
  Elizabeth McNally, MD, PhD

• Debate: Pros and cons of genetic testing.  
  Erin Miller, MS, GSC and Benjamin Helm, MS, GSC

• How do we study the financial implications of genetic testing?  
  Andrew Landstrom, MD, PhD

• General discussion and summary

4:40-5:00 pm Recap and Next Steps
5:00 pm Reception and Dinner

Friday, May 1, 2020

8:00-8:30 am Breakfast

8:30-10:30 am Restrictive Cardiomyopathy  
Session Leaders: Joseph Rossano, MD, Michael Burch MB, Ch B, MRCP, MSc

• Overview of current knowledge.  
  Susan Denfield, MD

• Risk stratification in RCM.  
  Michael Burch MB, Ch B, MRCP, MSc

• Secondary causes of RCM.  
  Yuk Law, MD

• Medical therapy for diastolic dysfunction: right around the corner or waiting for Godot?  
  Paul Kantor, MBBCh, MSc

• Moderated panel discussion
  o Moderators  
    Michael Burch MB, Ch B, MRCP, MSc, Joseph Rossano, MD
  o Panel  
    Robert Weintraub, MB BS, Susan Denfield, MD,  
    Jeff Towbin, MD, Shelley Miyamoto, MD

10:30-10:40 am Coffee Break

10:40-12:30 pm Noncompaction Cardiomyopathy  
Session Leaders: Melanie Everitt, MD, Brian Feingold, MD, John Lynn Jefferies, MD, PhD

• Spectrum of phenotypes of LVNC in children.  
  Jeff Towbin, MD

• Spectrum of phenotype of LVNC in adults.  
  Eloisa Arbustini, MD
• Molecular and histopathologic features of LVNC.
  Weinian Shou, PhD

• LVNC Imaging: diagnostic criteria for echo, CMR, CT and features of LVNC in Barth.
  Carolyn Taylor, MD

• Case presentations:
  o Isolated LVNC
    Ashwin Lal, MD
  o CHD with LVNC
    Thomas Ryan, MD

• Moderated Panel Discussion
  o Moderator
    Brian Feingold, MD
  o Panel
    John Lynn Jefferies, MD, MPH, Jeff Towbin, MD, Eloisa Arbustini, MD, Carolyn Taylor, MD, Weinian Shou, PhD

12:30-1:15 pm  Lunch

1:15-3:15 pm  Arrhythmogenic Cardiomyopathy
  Session Leaders: Jeff Towbin, MD, Teresa Lee, MD
  • Clinical and genetic features of arrhythmogenic cardiomyopathy.
    Luisa Mestroni, MD
  • Pathophysiology of arrhythmogenic cardiomyopathy and protein/pathway targeted therapy
    Jeffrey Saffitz, MD, PhD
  • Unresolved areas and research priorities
    Dominic Abrams, MD
  • Gene based diagnostics and therapeutics
    Teresa Lee, MD
  • Diagnostic barriers
    Pamela Woodard, MD
  • Treatment barriers and exercise guidelines
    Joseph Rossano, MD
  • Next steps to achieving better outcomes
    John Lynn Jefferies, MD, MPH
  • General discussion and summary.

3:15-4:00 pm  Future Directions for the Pediatric Cardiomyopathy Community
  • Steven Colan, MD

4:00 pm  Meeting Adjourns